Phase I and II studies of cytostatic hexitol derivatives: the role of alkylating metabolites?
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D004261:DNA Replication / Q000187:drug effects; D003961:Dianhydrogalactitol / Q000627:therapeutic use* / Q000633:toxicity; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008936:Mitolactol / Q000378:metabolism / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009374:Neoplasms, Experimental / Q000188:drug therapy; D013329:Structure-Activity Relationship; D013402:Sugar Alcohols / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013402:Sugar Alcohols; D003961:Dianhydrogalactitol; D008936:Mitolactol